Euthyreote Schilddrüsenknoten

Schilddrüsenknoten sind oftmals Zufallsbefunde und treten in milden Jodmangelgebieten Deutschlands bei 16-30 % der Erwachsenen, mit Bevorzugung des weiblichen Geschlechtes auf [23] [25] [28]. Sie stellen damit die häufigste endokrinologische Erkrankung dar [40]. Schilddrüsenknoten bergen die Risiken, maligne zu entarten oder Schilddrüsenfunktionsstörungen hervorzurufen. Diese Risiken sind von verschiedenen Faktoren, wie Umwelteinflüssen, Größe und Stoffwechselaktivität der Knoten, Alter und Geschlecht der Patienten abhängig. Deshalb müssen diese Einflüsse bei der Therapie von Knoten innerhalb und außerhalb von Studien Berücksichtigung finden. Die diagnostische Schwierigkeit liegt in der Unterscheidung zwischen benignen und malignen Läsionen.

Derzeit gibt es [im Gegensatz zu z. B. Nebenniereninzidentalomen, [26]] keine evidenzbasierten Richtlinien für den Umgang mit Schilddrüseninzidentalomen.

1 Der Beitrag „ Euthyreoter Schilddrüsenknoten: Therapieziele, Resultate und Perspektiven der medikamentösen Therapie” erscheint im nächsten Heft (Nr. 45).

Literatur

• 1 Baldini M, Gallazzi M, Orsatti A, Fossati S, Leonardi P, Cantalamessa L. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.  J Intern Med. 2002;  251 407-414
• 2 Baltisberger B L, Minder C E, Burgi H. Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency.  Eur J Endocrinol. 1995;  132 546-549
• 3 Belfiore A, Garofalo M R, Giuffrida D. et al . Increased aggressiveness of thyroid cancer in patients with Graves’ disease.  J Clin Endocrinol Metab. 1990;  70 830-835
• 4 Belfiore A, La Rosa G L, La Porta G A. et al . Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity.  Am J Med. 1992;  93 363-369
• 5 Belfiore A, La Rosa G L, Padova G, Sava L, Ippolito O, Vigneri R. The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area.  Cancer. 1987;  60 3096-3102
• 6 Berghout A, Wiersinga W M, Smits N J, Touber J L. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter.  Am J Med. 1990;  89 602-608
• 7 Brabant G, Bergmann P, Kirsch C M, Kohrle J, Hesch R D, von zur Muhlen A. Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man.  Metabolism. 1992;  41 1093-1096
• 8 Bray G A. Increased sensitivity of the thyroid in iodine-depleted rats to the goitrogenic effects of thyrotropin.  J Clin Invest. 1968;  47 1640-1647
• 9 Carrillo J F, Frias-Mendivil M, Ochoa-Carrillo F J, Ibarra M. Accuracy of fine-needle aspiration biopsy of the thyroid combined with an evaluation of clinical and radiologic factors.  Otolaryngol Head Neck Surg. 2000;  122 917-921
• 10 Celani M F. Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter.  Exp Clin Endocrinol. 1993;  101 326-332
• 11 Danese D, Sciacchitano S. The thyroid nodule. Diagnostic considerations.  Minerva Endocrinol. 1993;  18 129-137
• 12 Daniels G H. Thyroid nodules and nodular thyroids: a clinical overview.  Compr Ther. 1996;  22 239-250
• 13 Daumerie C, Ayoubi S, Rahier J, Buysschaert M, Squifflet J P. Prevalence of thyroid cancer in hot nodules.  Ann Chir. 1998;  52 444-448
• 14 Dawson T, Wynford-Thomas D. Does autocrine growth factor secretion form part of a mechanism which paradoxically protects against tumour development?.  Br J Cancer. 1995;  71 1136-1141
• 15 Dayan C M, Daniels G H. Chronic autoimmune thyroiditis.  N Engl J Med. 1996;  335 99-107
• 16 Dugrillon A, Gartner R. delta-Iodolactones decrease epidermal growth factor-induced proliferation and inositol-1,4,5-trisphosphate generation in porcine thyroid follicles-a possible mechanism of growth inhibition by iodide.  Eur J Endocrinol. 1995;  132 735-743
• 17 Eggo M C, Sheppard M C. Autocrine growth factors produced in the thyroid.  Mol Cell Endocrinol. 1994;  100 97-102
• 18 Filetti S, Bidart J M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.  Eur J Endocrinol. 1999;  141 443-457
• 19 Führer D HH, Ruschenburg I, Paschke R. Diagnostik des Schilddrüsenknotens.  Dt Ärzteblatt. 2001;  38 2094-2100
• 20 Gartner R, Dugrillon A, Bechtner G. Evidence that iodolactones are the mediators of growth inhibition by iodine on the thyroid.  Acta Med Austriaca. 1996;  23 47-51
• 21 Gharib H, James E M, Charboneau J W, Naessens J M, Offord K P, Gorman C A. Suppressive therapy with levothyroxine for solitary thyroid nodules. A double-blind controlled clinical study.  N Engl J Med. 1987;  317 70-75
• 22 Greer M A, Studer H, Kendall J W. Studies on the pathogenesis of colloid goiter.  Endocrinology. 1967;  81 623-632
• 23 Gruning T, Zophel K, Wunderlich G, Franke W G. Prevalence of goiter and iodine deficiency in Saxony is less than previously assumed: A study 6 years after discontinuation of general iodization of table salt.  Med Klin. 2001;  96 1-8
• 24 Grussendorf M. Therapy of euthyroid iron deficiency goiter. Effectiveness of a combination of L-thyroxine and 150 micrograms iodine in comparison with mono-L-thyroxine.  Med Klin. 1996;  91 489-493
• 25 Hampel R, Kulberg T, Klein K. et al . Goiter incidence in Germany is greater than previously suspected.  Med Klin. 1995;  90 324-329
• 26 Health. NIo .State of the science statement. Management of the clinically inapparent adrenal mass (incidentaloma). 2002
• 27 Hicks D G, LiVolsi V A, Neidich J A, Puck J M, Kant J A. Clonal analysis of solitary follicular nodules in the thyroid.  Am J Pathol. 1990;  137 553-562
• 28 Hoermann R, Quadbeck B. Course of thyroid nodules.  Exp Clin Endocrinol Diabetes. 1998;  106 S27-28
• 29 Kahaly G, Dienes H P, Beyer J, Hommel G. Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter.  J Clin Endocrinol Metab. 1997;  82 4049-4053
• 30 Klemenz B, Forster G, Wieler H. et al . Combination therapy of endemic goiter with two different thyroxine/iodine combinations.  Nuklearmedizin. 1998;  37 101-106
• 31 Kopp P, Kimura E T, Aeschimann S. et al . Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters.  J Clin Endocrinol Metab. 1994;  79 134-139
• 32 Krohn K, Fuhrer D, Holzapfel H P, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations.  J Clin Endocrinol Metab. 1998;  83 130-134
• 33 Krohn K, Paschke R. Clinical review 133: Progress in understanding the etiology of thyroid autonomy.  J Clin Endocrinol Metab. 2001;  86 3336-3345
• 34 Krohn K, Paschke R. Somatic mutations in thyroid nodular disease.  Mol Genet Metab. 2002;  75 202-208
• 35 Krohn K, Reske A, Ackermann F, Muller A, Paschke R. Ras mutations are rare in solitary cold and toxic thyroid nodules.  Clin Endocrinol (Oxf). 2001;  55 241-248
• 36 Kuma K, Matsuzuka F, Kobayashi A. et al . Outcome of long standing solitary thyroid nodules.  World J Surg. 1992;  16 583-587 , discussion 587-588.
• 37 Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term follow-up.  World J Surg. 1994;  18 495-498
• 38 La Rosa G L, Lupo L, Giuffrida D, Gullo D, Vigneri R, Belfiore A. Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.  Ann Intern Med. 1995;  122 1-8
• 39 Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies.  Am J Clin Pathol. 1988;  90 72-76
• 40 Mazzaferri E L. Management of a solitary thyroid nodule.  N Engl J Med. 1993;  328 553-559
• 41 Namba H, Matsuo K, Fagin J A. Clonal composition of benign and malignant human thyroid tumors.  J Clin Invest. 1990;  86 120-125
• 42 Papini E, Guglielmi R, Bianchini A. et al . Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.  J Clin Endocrinol Metab. 2002;  87 1941-1946
• 43 Papini E, Petrucci L, Guglielmi R. et al . Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.  J Clin Endocrinol Metab. 1998;  83 780-783
• 44 Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases.  N Engl J Med. 1997;  337 1675-1681
• 45 Paschke R, Neumann S. Sodium/iodide symporter mRNA expression in cold thyroid nodules.  Exp Clin Endocrinol Diabetes. 2001;  109 45-46
• 46 Pisarev M A, Kleiman de Pisarev D L. Biochemistry of thyroid regulation under normal and abnormal conditions.  J Endocrinol Invest. 1980;  3 317-329
• 47 Reverter J L, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A. Suppressive therapy with levothyroxine for solitary thyroid nodules.  Clin Endocrinol (Oxf). 1992;  36 25-28
• 48 Richter B, Neises G, Clar C. Pharmacotherapy for thyroid nodules. A systematic review and meta- analysis.  Endocrinol Metab Clin North Am. 2002;  31 699-722
• 49 Rojeski M T, Gharib H. Nodular thyroid disease. Evaluation and management.  N Engl J Med. 1985;  313 428-436
• 50 Russo D, Bulotta S, Bruno R. et al . Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter.  Eur J Endocrinol. 2001;  145 591-597
• 51 Saller B, Hoermann R, Ritter M M, Morell R, Kreisig T, Mann K. Course of thyroid iodine concentration during treatment of endemic goitre with iodine and a combination of iodine and levothyroxine.  Acta Endocrinol (Copenh). 1991;  125 662-667
• 52 Sawin C T, Geller A, Wolf P A. et al . Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.  N Engl J Med. 1994;  331 1249-1252
• 53 Schmutzler C, Kohrle J. Implications of the molecular characterization of the sodium-iodide symporter (NIS).  Exp Clin Endocrinol Diabetes. 1998;  106 S1-10
• 54 Studer H GM. A study of the mechanisms involved in the production of iodine-deficient goiter.  Acta Endocrinol (Copenh). 1965;  49 610-628
• 55 Terzioglu T, Tezelman S, Onaran Y, Tanakol R. Concurrent hyperthyroidism and thyroid carcinoma.  Br J Surg. 1993;  80 1301-1302
• 56 Tonacchera M, Viacava P, Agretti P. et al . Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.  J Clin Endocrinol Metab. 2002;  87 352-357
• 57 Tonacchera M, Vitti P, Agretti P. et al . Functioning and nonfunctioning thyroid adenomas involve different molecular pathogenetic mechanisms.  J Clin Endocrinol Metab. 1999;  84 4155-4158
• 58 Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.  J Clin Endocrinol Metab. 1996;  81 4278-4289
• 59 Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases.  J Clin Endocrinol Metab. 1997;  82 1589-1593
• 60 Wemeau J L, Caron P, Schvartz C. et al . Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo- controlled trial by the French Thyroid Research Group.  J Clin Endocrinol Metab. 2002;  87 4928-4934
• 61 Wynford-Thomas D. Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms.  Horm Res. 1997;  47 145-157
• 62 Wynford-Thomas D, Stringer B M, Williams E D. Dissociation of growth and function in the rat thyroid during prolonged goitrogen administration.  Acta Endocrinol (Copenh). 1982;  101 210-216
• 63 Yang G C, LiVolsi V A, Baloch Z W. Thyroid microcarcinoma: fine-needle aspiration diagnosis and histologic follow-up.  Int J Surg Pathol. 2002;  10 133-139
• 64 Zelmanovitz F, Genro S, Gross J L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses.  J Clin Endocrinol Metab. 1998;  83 3881-3885

1 Der Beitrag „ Euthyreoter Schilddrüsenknoten: Therapieziele, Resultate und Perspektiven der medikamentösen Therapie” erscheint im nächsten Heft (Nr. 45).